Multiple lineage switches in KMT2A rearranged infant leukemia, responsive to combination therapy with CPX-351 and inotuzumab

Pediatr Blood Cancer. 2023 Nov;70(11):e30645. doi: 10.1002/pbc.30645. Epub 2023 Aug 28.

Authors

Justin Sperlazza¹, Jonathan Galeotti², George Hucks¹, Thomas B Alexander^{1

2}

Affiliations

¹ Division of Pediatric Hematology-Oncology, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.
² Department of Pathology and Laboratory Medicine, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.

PMID: 37638847
DOI: 10.1002/pbc.30645

No abstract available

Publication types

Letter

MeSH terms

Cytarabine*
Daunorubicin
Humans
Infant
Leukemia*

Substances

CPX-351
Cytarabine
Daunorubicin